Medifast Return on Equity (ROE) Growth & History (MED)

Medifast's return on equity was −9.13% for fiscal 2025.

View full Medifast company overview

Medifast annual return on equity history

Medifast annual return on equity

Fiscal yearPeriod endedReturn on equityChange (percentage points)
20252025-12-31−9.13%−10.15 pp
20242024-12-311.02%−54.75 pp
20232023-12-3155.77%−24.54 pp
20222022-12-3180.31%−10.89 pp
20212021-12-3191.20%+12.70 pp
20202020-12-3178.49%+5.66 pp
20192019-12-3172.84%+21.10 pp
20182018-12-3151.74%+24.37 pp
20172017-12-3127.37%+8.05 pp
20162016-12-3119.32%−4.41 pp
20152015-12-3123.73%+8.99 pp
20142014-12-3114.74%−10.60 pp
20132013-12-3125.34%+6.00 pp
20122012-12-3119.34%−6.17 pp
20112011-12-3125.51%−7.24 pp
20102010-12-3132.75%

Medifast return on equity trends

Over the last five fiscal years, Medifast's return on equity decreased from 78.49% to −9.13%, a change of −87.62 percentage points. The latest reported quarter, Q2 2026, shows −1.57%.

About the metric

What return on equity (ROE) means

Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.

Calculation and source

How return on equity is calculated

TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Medifast source filings ↗

Community posts

It’s quiet here.

No posts about MED yet. Start the conversation.

Write the first post